Literature DB >> 3919114

Studies on the ability of alginate to act as a protective immunogen against infection with Pseudomonas aeruginosa in animals.

D E Woods, L E Bryan.   

Abstract

Most patients with cystic fibrosis become colonized and infected with mucoid Pseudomonas aeruginosa. The major component of the mucoid material has been identified as the polysaccharide alginic acid. The present work was undertaken to determine whether antibody to alginate is protective in a model of chronic lung infection with P. aeruginosa in rats. Bacterial clearance was associated with a rise in titers of antibody to alginate. In a number of animals a rise in antibody titers was not seen, and in fact a decrease was noted at 30 days compared with 10 days. This observation suggested the possibility of immune complex formation due to antigen excess. Evidence for immune complex deposition in tissues was obtained by immunofluorescence studies. Thus antibody to alginate may offer strain-dependent protection against chronic lung infection with P. aeruginosa in rats; however, immune complex formation should be considered as a possible consequence of immunization with alginate.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3919114     DOI: 10.1093/infdis/151.4.581

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  15 in total

1.  Effect of oral immunization with Pseudomonas aeruginosa on the development of specific antibacterial immunity in the lungs.

Authors:  J Freihorst; J M Merrick; P L Ogra
Journal:  Infect Immun       Date:  1989-01       Impact factor: 3.441

2.  A simple alfalfa seedling infection model for Pseudomonas aeruginosa strains associated with cystic fibrosis shows AlgT (sigma-22) and RhlR contribute to pathogenesis.

Authors:  Laura Silo-Suh; Sang-Jin Suh; Pamela A Sokol; Dennis E Ohman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-08       Impact factor: 11.205

3.  Pseudomonas aeruginosa outer membrane lipoprotein I gene: molecular cloning, sequence, and expression in Escherichia coli.

Authors:  M Duchêne; C Barron; A Schweizer; B U von Specht; H Domdey
Journal:  J Bacteriol       Date:  1989-08       Impact factor: 3.490

4.  Adaptations of Pseudomonas aeruginosa to the cystic fibrosis lung environment can include deregulation of zwf, encoding glucose-6-phosphate dehydrogenase.

Authors:  Laura Silo-Suh; Sang-Jin Suh; Paul V Phibbs; Dennis E Ohman
Journal:  J Bacteriol       Date:  2005-11       Impact factor: 3.490

5.  Characterization of the binding of Pseudomonas aeruginosa alginate to human epithelial cells.

Authors:  P Doig; N R Smith; T Todd; R T Irvin
Journal:  Infect Immun       Date:  1987-06       Impact factor: 3.441

6.  Immunization with Pseudomonas aeruginosa vaccines and adjuvant can modulate the type of inflammatory response subsequent to infection.

Authors:  H K Johansen; F Espersen; S J Cryz; H P Hougen; A Fomsgaard; J Rygaard; N Høiby
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

7.  Outer membrane protein F preparation of Pseudomonas aeruginosa as a vaccine against chronic pulmonary infection with heterologous immunotype strains in a rat model.

Authors:  H E Gilleland; L B Gilleland; J M Matthews-Greer
Journal:  Infect Immun       Date:  1988-05       Impact factor: 3.441

8.  Serial isolates of Pseudomonas aeruginosa from a cystic fibrosis patient have identical pilin sequences.

Authors:  B L Pasloske; A M Joffe; Q Sun; K Volpel; W Paranchych; F Eftekhar; D P Speert
Journal:  Infect Immun       Date:  1988-03       Impact factor: 3.441

9.  Purification and characterization of an extracellular protease from Pseudomonas cepacia.

Authors:  A I McKevitt; S Bajaksouzian; J D Klinger; D E Woods
Journal:  Infect Immun       Date:  1989-03       Impact factor: 3.441

10.  Mucosal and systemic immunizations with killed Pseudomonas aeruginosa protect against acute respiratory infection in rats.

Authors:  A W Cripps; M L Dunkley; R L Clancy
Journal:  Infect Immun       Date:  1994-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.